The Wall Street Journal is looking past the FDA’s official ending of the GLP-1 shortages and into...
More great coverage of GLP-1s
The Royal Society of Chemistry's Chemistry World has a terrific piece on the ending of the semaglutide shortage and the issues that APC — and compounders in general — have with how the FDA handled it. Bonus: “Ending of US weight-loss drug shortages prompts compounder complaints” includes important (and well-spoken, if we do say so) perspective from APC’s Tenille Davis.
